Monitor for dilution impact once offering terms are finalized; the lack of minimum funding threshold increases execution risk. The company's survival depends on this capital raise succeeding.
Price Chart
Executive Summary
Lantern Pharma is conducting a best-efforts common stock offering to raise capital, following its recent earnings report that highlighted clinical progress but revealed a cash position of only $10.1 million. The offering has no minimum size and proceeds will fund working capital and general corporate purposes.
Key Facts
- Company is raising capital through a best-efforts common stock offering with no minimum size requirement
- Recent earnings report showed $10.1 million in cash as of December 31, 2025, with substantial doubt about going concern
- Offering proceeds will be used for working capital and general corporate purposes with broad management discretion
- Stock has high volatility (traded between $1.11 and $5.74 in past year) and market cap of $13 million
- No specific financial terms disclosed in the filing (number of shares, price, or expected proceeds)
Financial Impact
Dilutive capital raise to address liquidity concerns, size unknown
Risk Factors
- Substantial doubt about going concern due to limited cash runway
- Best-efforts offering with no minimum may raise insufficient capital
- Significant shareholder dilution from equity issuance
- High stock volatility and low market cap increase investment risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-013685 |
| Document: 0001493152-26-013685-index-headers.html | 0001493152-26-013685 |
| Document: 0001493152-26-013685-index.html | 0001493152-26-013685 |
| Document: 0001493152-26-013685.txt | 0001493152-26-013685 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $0.6564 | awaiting T+60 | — | $0.6240 (+4.94%) |
Oct 13, 2026 13d ago | SC 13G/A | $0.7107 | awaiting T+60 | — | $0.6240 (−12.20%) |
Oct 1, 2026 25d ago | 8-K | $0.8601 | awaiting T+60 | — | $0.6240 (+27.45%) |
Sep 30, 2026 26d ago | 8-K | $1.00 | awaiting T+60 | — | $0.6240 (+37.60%) |
Sep 30, 2026 26d ago | 424B5 | $1.01 | awaiting T+60 | — | $0.6240 (+38.22%) |
Sep 23, 2026 4w ago | 8-K | $1.21 | awaiting T+60 | — | $0.6240 (−48.43%) |
Sep 23, 2026 4w ago | 8-K | $1.39 | awaiting T+60 | — | $0.6240 (−55.11%) |
Aug 14, 2026 10w ago | 8-K | $2.65 | awaiting T+60 | — | $0.6240 (−76.45%) |
Jun 22, 2026 18w ago | EFFECT | $3.88 $1.70 | ▲ +56.19% | ▲ +57.93% | $0.6240 (+83.92%) |
May 15, 2026 23w ago | 8-K | $3.00 $2.66 | ▼ −11.33% | ▼ −16.18% | $0.6240 (−79.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers